These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22105817)

  • 1. Thymic malignancies: from clinical management to targeted therapies.
    Kelly RJ; Petrini I; Rajan A; Wang Y; Giaccone G
    J Clin Oncol; 2011 Dec; 29(36):4820-7. PubMed ID: 22105817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study.
    Aisner SC; Dahlberg S; Hameed MR; Ettinger DS; Schiller JH; Johnson DH; Aisner J; Loehrer PJ
    J Thorac Oncol; 2010 Jun; 5(6):885-92. PubMed ID: 20421818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymic tumors: relevant molecular data in the clinic.
    Girard N
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies for thymic malignancies.
    Girard N
    Thorac Surg Clin; 2011 Feb; 21(1):115-23, viii. PubMed ID: 21070993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do thymic malignancies respond to target therapies?
    Hu B; Rong H; Han Y; Li Q
    Interact Cardiovasc Thorac Surg; 2015 Jun; 20(6):855-9. PubMed ID: 25754373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic treatment of advanced thymic malignancies.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
    Simonelli M; Zucali PA; Suter MB; Lorenzi E; Rubino L; Fatuzzo G; Alloisio M; Santoro A
    Future Oncol; 2015; 11(8):1223-32. PubMed ID: 25832879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy and targeted agents for thymic malignancies.
    Girard N
    Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib in patients with advanced thymic malignancies: Cohort from the French RYTHMIC network.
    Remon J; Girard N; Mazieres J; Dansin E; Pichon E; Greillier L; Dubos C; Lindsay CR; Besse B
    Lung Cancer; 2016 Jul; 97():99-104. PubMed ID: 27237035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors.
    Serpico D; Trama A; Haspinger ER; Agustoni F; Botta L; Berardi R; Palmieri G; Zucali P; Gallucci R; Broggini M; Gatta G; Pastorino U; Pelosi G; de Braud F; Garassino MC
    Ann Oncol; 2015 May; 26(5):838-847. PubMed ID: 25411417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
    Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
    Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer.
    Forde PM; Kelly RJ
    J Thorac Oncol; 2013 Jun; 8(6):673-84. PubMed ID: 23591158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Agents in the Treatment of Thymic Malignancies.
    Merveilleux du Vignaux C; Maury JM; Girard N
    Curr Treat Options Oncol; 2017 Aug; 18(9):52. PubMed ID: 28795288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment updates in advanced thymoma and thymic carcinoma.
    Gubens MA
    Curr Treat Options Oncol; 2012 Dec; 13(4):527-34. PubMed ID: 22961051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precise Diagnosis and Treatment of Thymic Epithelial Tumors Based on Molecular Biomarkers.
    Du J; Zhou XJ
    Crit Rev Oncog; 2017; 22(5-6):507-514. PubMed ID: 29604928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
    Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
    Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapy for advanced thymic tumors.
    Rajan A; Giaccone G
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S361-4. PubMed ID: 20859134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic treatments for thymoma and thymic carcinoma: A systematic review.
    Berghmans T; Durieux V; Holbrechts S; Jungels C; Lafitte JJ; Meert AP; Moretti L; Ocak S; Roelandts M; Girard N
    Lung Cancer; 2018 Dec; 126():25-31. PubMed ID: 30527189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.
    Thomas A; Rajan A; Berman A; Tomita Y; Brzezniak C; Lee MJ; Lee S; Ling A; Spittler AJ; Carter CA; Guha U; Wang Y; Szabo E; Meltzer P; Steinberg SM; Trepel JB; Loehrer PJ; Giaccone G
    Lancet Oncol; 2015 Feb; 16(2):177-86. PubMed ID: 25592632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.